ITP
TEVA icon

Iron Triangle Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Iron Triangle Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,217,730
Closed -$34.1M – 36
2025
Q1 		$34.1M Buy
2,217,730
+17,694
+0.8% +$316K 5.37% 4
2024
Q4 		$48.5M Buy
2,200,036
+256,246
+13% +$4.66M 5.34% 6
2024
Q3 		$35M Sell
1,943,790
-1,356,395
-41% -$23.7M 4.85% 8
2024
Q2 		$53.6M Buy
3,300,185
+530,321
+19% +$8.17M 5.45% 7
2024
Q1 		$39.1M Buy
2,769,864
+1,469,864
+113% +$18.5M 4% 12
2023
Q4 		$13.6M Buy
+1,300,000
New +$12.1M 1.76% 25
2020
Q2 		– Sell
-1,000,000
Closed -$8.98M – 33
2020
Q1 		$8.98M Buy
+1,000,000
New +$10.2M 3.47% 13

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Iron Triangle Partners's TEVA Position: Q2 2025 in Review

Iron Triangle Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 2,217,730 shares — an estimated $34.1M sold.

Iron Triangle Partners first reported a position in TEVA in Q1 2020 and held it in 7 quarters. The position peaked at $53.6M in Q2 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Iron Triangle Partners reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Iron Triangle Partners sold 2,217,730 Teva Pharmaceuticals shares in Q2 2025, an estimated $34.1M.
  • Iron Triangle Partners first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • Iron Triangle Partners's Teva Pharmaceuticals position peaked at $53.6M in Q2 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Iron Triangle Partners's 13F filing for Q2 2025, filed 14 Aug 2025.